3.4Impact Factor
4.9CiteScore
22 daysTime to First Decision

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 18, Issue 12

October 2011 - 4 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (4)

Select all

Proceeding Paper

15 Citations

510 Views

Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective

A. M. Oza,
V. Castonguay,
D. Tsoref,
I. Diaz–Padilla,
K. Karakasis,
H. Mackay,
S. Welch,
J. Weberpals,
P, Hoskins and
M. Plante
+ 13 authors

Curr. Oncol.2011, 18(12), 20-27;https://doi.org/10.3747/co.v18i0.939

1 October 2011

Ovarian cancer is leading cause of gynecologic cancer mortality in Canada. To date, overall survival (os) has been the most-used endpoint in oncology trials because of its relevance and objectivity. However, as a result of various factors, including...

Full Article

Editorial

3 Citations

726 Views

2 Pages

The Significance of Progressionfree Survival as an Endpoint in Evaluating the Therapeutic Value of Antineoplastic Agents

J.A. Maroun

Curr. Oncol.2011, 18(12), 3-4;https://doi.org/10.3390/curroncol18120004

1 October 2011

In the last decade, thanks to the development of new and effective cytotoxic and biologic agents, significant progress has been achieved in the treatment of various forms of cancer. [...]

Full Article

Article

26 Citations

1,513 Views

9 Pages

Progression-Free Survival as a Clinical Trial Endpoint in Advanced Renal Cell Carcinoma

S.J. Hotte,
G.A. Bjarnason,
D.Y.C. Heng,
M.A.S. Jewett,
A. Kapoor,
C. Kollmannsberger,
J. Maroun,
L.A. Mayhew,
S. North and
M.N. Reaume
+ 7 authors

Curr. Oncol.2011, 18(12), 11-19;https://doi.org/10.3747/co.v18is2.958

1 October 2011

Traditionally, overall survival (os) has been considered the “gold standard” for evaluating new systemic oncologic therapies, because death is easy to define, is easily compared across disease sites, and is not subject to investigator bias. However,...

Full Article

Article

20 Citations

1,270 Views

6 Pages

Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal Cancer

S. Gill,
S. Berry,
J. Biagi,
C. Butts,
M. Buyse,
E. Chen,
D. Jonker,
C. Mărginean,
B. Samson and
J. Stewart
+ 3 authors

Curr. Oncol.2011, 18(12), 5-10;https://doi.org/10.3747/co.v18is2.941

1 October 2011

In recent years, significant advances have been made in the management of metastatic colorectal cancer. Traditionally, an improvement in overall survival has been considered the “gold standard”—the most convincing measure of efficacy. However, overal...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Curr. Oncol. - ISSN 1718-7729

Imprint

Download Flyer